Volume 14 Supplement 7

Proceedings of the 10th Edition of the Scientific Days of the National Institute for Infectious Diseases "Prof Dr Matei Bals"

Open Access

The experience of the National Institute for Infectious Diseases "Prof. Dr. Matei Balş" in bacterial resettlement therapy trough fecal microbiota transplant in recurrent infections with C. difficile

  • Cătălin Apostolescu1Email author,
  • Loredana Benea1,
  • Valeriu Gheorghiță1,
  • Adina Ilie1 and
  • Cristina Tenea1
BMC Infectious Diseases201414(Suppl 7):O32

https://doi.org/10.1186/1471-2334-14-S7-O32

Published: 15 October 2014

Background

The increasing frequency of C. difficile infections and the increased frequency of relapses imposed implementation of new treatment alternatives.

Methods

Starting with July 2013, in the National Institute for Infectious Diseases "Prof. Dr. Matei Balş" we performed 32 therapies in patients with relapsing infections trough bacterial re-colonization.

Results

We used as donors blood relatives (children, grandchildren) in 68.8% and in 31.2% cases we used stools from others. The success rate at 90 days was 96.8%. This success rate was achieved with a single procedure in 74.1% of cases, with two procedures in 22.5% and in 3.2% of cases with three procedures. The success rate was significantly higher in the first group.

Conclusion

Although the success of this maneuver is significantly higher than the standard antibiotic treatment, there is need to deepen the experience before generalizing it.

Authors’ Affiliations

(1)
National Institute for Infectious Diseases "Prof. Dr. Matei Balş"

Copyright

© Apostolescu et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement